We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tucatinib Together With Pembrolizumab and Trastuzumab (TUGETHER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04789096
Recruitment Status : Not yet recruiting
First Posted : March 9, 2021
Last Update Posted : September 6, 2022
Sponsor:
Information provided by (Responsible Party):
Breast Cancer Trials, Australia and New Zealand

Brief Summary:

Women or men with HER2-positive, metastatic breast cancer, who have progressed on previous treatment, will receive tucatinib in combination with:

  • Pembrolizumab and trastuzumab (PD-L1 positive); or
  • Pembrolizumab, trastuzumab and capecitabine (PD-L1 negative)

Condition or disease Intervention/treatment Phase
Breast Cancer HER2-positive Breast Cancer Drug: Tucatinib Drug: Pembrolizumab Drug: Trastuzumab Drug: Capecitabine Phase 2

Detailed Description:

Despite significant advances in systemic treatment options, advanced HER2-positive breast cancer post treatment with trastuzumab, pertuzumab and T-DM1 still remains incurable, with brain metastases remaining a major cause of patient morbidity and mortality.

HER2-positive breast cancers have relatively high tumour infiltrating lymphocytes (TILs) that may be targeted with immune checkpoint blockade. Studies in metastatic breast cancer with PD1 or PD-L1 inhibition have shown an overall survival (OS) benefit for those that are enriched for pre-existing immunity, such as positive expression of PD-L1 protein or TILs present.

One of the main areas of disease progression in HER2 positive disease is in the central nervous system (CNS), supporting the need to find an effective combination for patients with brain metastases.

Tucatinib (ONT-380) is a potent, highly selective, oral HER2 small molecule tyrosine kinase inhibitor (TKI) with demonstrated clinical benefit notable for its minimal inducement of EGFR-type toxicities when administered in combination-type studies including proven intra-cranial efficacy in studies of patients with brain metastases.

The investigators hypothesise that the combination of tucatinib with trastuzumab and PD-1 inhibition will result in a similar ORR as that seen in HER2CLIMB, along with comparable PFS and duration of response, particularly through prevention and treatment of CNS metastases. The advantage of adding PD-1 inhibition and omitting capecitabine in the PD-L1 positive group is to increase the durability of the response, with hopefully less added toxicity for patients. The investigators believe this regimen will result in comparable outcomes as those seen in HER2CLIMB, with fewer adverse events. In the PD-L1 negative cohort, the HER2CLIMB regimen (tucatinib + capecitabine) will be used with the addition of pembrolizumab with the hypothesis that its anti-tumour activity may overcome the lower immunogenicity of this subgroup. Importantly, the side effect profiles of all agents in the proposed combination are non-overlapping and this combination provides a unique opportunity for excellent tolerability and durable disease control in this patient group.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Non-comparative
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Two-arm, Non-comparative, Multicentre Study of Tucatinib (ONT-380), Pembrolizumab and Trastuzumab in Patients With Pre-treated Advanced HER2-positive Breast Cancer
Estimated Study Start Date : December 2022
Estimated Primary Completion Date : June 2024
Estimated Study Completion Date : June 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: PD-L1 positive

Participants will receive:

  • Tucatinib (oral) at a dose of 300 mg BD on day 1-21 of each 21-day cycle
  • Pembrolizumab will be administered at a dose of 200 mg IV on day 1 of each 21 day cycle
  • Trastuzumab will be given as a loading dose of 8 mg/kg IV (if loading required, otherwise 6 mg/kg) on day 1 followed by 6 mg/kg on day 1 of each 21 day cycle.
Drug: Tucatinib
Oral tablet
Other Name: Tukysa

Drug: Pembrolizumab
Intravenous
Other Name: Keytruda

Drug: Trastuzumab
Intravenous
Other Name: Herceptin

Experimental: PD-L1 negative

Participants will receive:

  • Tucatinib (oral) at a dose of 300 mg BD on day 1-21
  • Capecitabine (oral) at a dose of 1000 mg/m^2 BD on day 1-14 of each 21-day cycle
  • Pembrolizumab will be administered at a dose of 200 mg IV on day 1 of each 21 day cycle
  • Trastuzumab will be given as a loading dose of 8 mg/kg IV (if loading required, otherwise 6 mg/kg) on day 1 followed by 6 mg/kg on day 1 of each 21 day cycle.
Drug: Tucatinib
Oral tablet
Other Name: Tukysa

Drug: Pembrolizumab
Intravenous
Other Name: Keytruda

Drug: Trastuzumab
Intravenous
Other Name: Herceptin

Drug: Capecitabine
Oral tablet
Other Name: Xeloda




Primary Outcome Measures :
  1. Objective Response Rate (ORR) in the PD-L1 positive cohort [ Time Frame: Through to study completion, an average of 24 months ]
    Defined as complete response (CR) or partial response (PR) assessed as per RECIST 1.1


Secondary Outcome Measures :
  1. Objective response rate (ORR) in the PD-L1 negative cohort [ Time Frame: Through to study completion, an average of 24 months ]
    Defined as complete response (CR) or partial response (PR) assessed as per RECIST 1.1

  2. Progression free survival (PFS) in each PD-L1 cohort [ Time Frame: From the time of registration until documented disease progression by RECIST 1.1 or death due to any cause (whichever occurs first), assessed up to 24 months ]
    Defined as the time from start of study treatment until documented disease progression by RECIST 1.1 or death due to any cause (whichever occurs first) based on local investigator assessment.

  3. Duration of response (DoR) in each PD-L1 cohort [ Time Frame: From the time of registration to first documentation of progressive disease or death, assessed up to 24 months ]
    Defined as the time from first documentation of CR or PR by RECIST 1.1 to first documentation of progressive disease or death, in the subset of participants with objective response.

  4. Clinical benefit rate (CBR) in each PD-L1 cohort [ Time Frame: From time of registration to CR or PR, assessed up to 24 months ]
    Defined as stable disease (SD) for >= 6 months after starting study treatment, or best response of CR or PR.

  5. Overall survival (OS) in each PD-L1 cohort [ Time Frame: From time of registration until death from any cause, assessed at 24 months ]
    Defined as from the time from start of study treatment to death from any cause

  6. Incidence of treatment-emergent adverse events [Safety] [ Time Frame: From registration until 30 days after end of study treatment ]
    Assessed as worst grade of adverse events (AEs) and serious adverse events (SAE) documented using NCI-CTCAE 5.0.

  7. Incidence of treatment-emergent adverse events [Tolerability of tucatinib] [ Time Frame: From start of study treatment to the end of study treatment, assessed at 24 months ]
    Assessed by tucatinib dose holding, dose reduction, drug discontinuation.

  8. Incidence of treatment-emergent adverse events [Tolerability of pembrolizumab] [ Time Frame: From start of study treatment to end of study treatment, assessed at 24 months ]
    Assessed by pembrolizumab dose holding, dose reduction, drug discontinuation.


Other Outcome Measures:
  1. CNS progression in each PD-L1 cohort in participants with or without evidence of brain metastases at baseline by local image review. [ Time Frame: From the start of study treatment to the date of first CNS progression, assessed at 24 months ]
    Time to CNS progression per RECIST 1.1 measured from the start of study treatment to the date of first CNS progression. Non-CNS progression and death will be considered competing events.

  2. Extra-cranial PFS in each PD-L1 cohort [ Time Frame: Until documented disease progression, assessed at 24 months ]
    PFS excluding CNS progression defined as the time from start of study treatment until documented disease progression by RECIST 1.1 or death due to any cause (whichever occurs first) based on local investigator assessment.

  3. PFS in participants with or without evidence of brain metastases at baseline in each PD-L1 cohort [ Time Frame: Until documented disease progression or death due to any cause, assessed at 24 months ]
    Defined as the time from start of study treatment until documented disease progression by RECIST 1.1 or death due to any cause (whichever occurs first) based on local investigator assessment.

  4. Identify potential biomarkers of response - PD-L1 [ Time Frame: At screening ]
    PD-L1 protein status (positive or negative) will be evaluated centrally by immunohistochemistry (IHC) using the 22C3 pharmDx PD-L1 assay. PD-L1 is positive by a MSD Combined Positive Score (CPS) of ≥ 10.

  5. Identify potential biomarkers of response - Tumour infiltrating lymphocytes (TILs) [ Time Frame: At baseline and 3 weeks after starting study treatment. ]
    Stromal Tumour Infiltrating Lymphocyte percentage (TIL%) will be recorded as per www.tilsinbreastcancer.org. Objective responses will be assessed as a function of TILs adjusted for other clinico-pathological factors, the hypothesis being that high levels of TILs will be associated with a higher rate of objective responses in this study.

  6. Identify potential biomarkers of response - DNA and RNA [ Time Frame: At baseline ]
    To understand the molecular landscape (mutations, rearrangements and copy number changes) associated with HER2-positive, PD-L1 expressing tumours as well as response or resistance to the investigational study treatment.

  7. Identify potential biomarkers of response - ctDNA [ Time Frame: Before first dose of study drug, before dose at Cycle 3 and Cycle 8 (each Cycle is 21 days), 30 days after stopping study treatment and/or at disease progression, assessed at 24 months ]
    To track and monitor tumour dynamics during treatment.

  8. Identify potential biomarkers of response - peripheral blood mononuclear cells (PBMC) [ Time Frame: At Baseline, every 6 weeks for 24 weeks, then every 9 weeks until disease progression, 30 days after stopping study treatment and/or at progression, assessed at 24 months ]
    To determine evidence of immune activation.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria (Pre-Registration):

  1. Has provided written, informed consent to participate in the study.
  2. Female or male, age ≥ 18 years.
  3. Local histologically confirmed HER2-positive unresectable loco-regional or metastatic breast cancer. HER2-positive according to ASCO CAP 2018 guidelines defined as:

    1. ISH testing with ERBB2-amplification as demonstrated by ratio ERBB2/centromeres ≥ 2.0 or mean gene copy number ≥ 6 OR
    2. 3+ staining by IHC.
  4. FFPE tumour samples (preferably two blocks) available from newly obtained biopsies of advanced disease for assessment of PD-L1, TILs status and correlative research. If new biopsies are not obtainable then primary/metastatic archival biopsies (preferably two samples) from within 12 months of registration may be provided.
  5. Must have previously received taxane, trastuzumab, pertuzumab and an antibody-drug conjugate (ADC) in either the (neo) adjuvant or advanced disease setting. Any number of prior lines of anti-HER2 therapy is acceptable.
  6. Have progression of unresectable locally advanced or metastatic breast cancer during or after last systemic therapy (as confirmed by investigator), or be intolerant of last systemic therapy.
  7. Have a life expectancy of at least 6 months, in the opinion of the investigator.
  8. Women of childbearing potential (WOCBP) and men with partners of childbearing potential must agree to use a highly effective contraception from the signing of informed consent until 7 months after the last dose of protocol treatment.

    Note: Use of oral, injectable or implant hormonal contraceptives or medicated IUD must stop before registration.

  9. Willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations during both the treatment and follow-up phases.

Inclusion Criteria (Registration):

In addition to the above listed pre-registration inclusion criteria, participants must fulfill all the following criteria before registration:

  1. Confirmed PD-L1 positive or PD-L1 negative status evaluated by IHC to determine treatment cohort. Note: the first 10 participants will be reviewed for PD-L1 positivity rates
  2. Have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  3. Have measurable disease assessable by RECIST v1.1.
  4. Must have one of the following (based on screening brain MRI):

    a) No evidence of brain metastases OR b) Untreated brain metastases not needing immediate local therapy. Participants with CNS measurable disease by RECIST 1.1 criteria, with or without measurable extracranial disease by RECIST are eligible. For participants with untreated CNS lesions > 2.0 cm on screening MRI, discussion with and approval from BCT and the Study Chair is required before registration OR c) Previously treated brain metastases: i) Brain metastases previously treated with local therapy may either be stable since treatment or may have progressed since prior local brain metastasis therapy, provided that there is no clinical indication for immediate re-treatment with local therapy in the opinion of the investigator.

    ii) Participants treated with CNS local therapy for newly identified lesions found on initial MRI performed during screening for this study may be eligible if the following criteria are met: (1) Time since whole brain radiation therapy (WBRT) is ≥ 21 days before registration, or (2) Time since stereotactic radiosurgery is ≥ 7 days before registration, or time since surgical resection is ≥ 28 days (3) Other sites of disease assessable by RECIST 1.1. are present.

  5. Relevant records of any CNS treatment must be available to allow for classification of target and non-target lesions.
  6. Have a left ventricular ejection fraction (LVEF) of ≥ 50% as assessed by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) documented within 4 weeks before registration.
  7. Have adequate haematological, coagulation, hepatic and renal functions within 7 days before registration as defined as:

    1. Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L
    2. Platelet count ≥ 100 x 10^9/L
    3. Haemoglobin ≥ 90 g/L
    4. Creatinine ≤ 1.5 x ULN or serum creatinine clearance > 40 mL/min by the Cockcroft-Gault formula or by 24-hour urine collection for determination of creatinine clearance:
    5. Serum total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN). In the case of known Gilbert's disease, serum total bilirubin < 2 x ULN is allowed
    6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x institutional ULN unless liver metastases are present, in which case it must be ≤ 5 x ULN
    7. International normalised ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN unless on medication known to alter INR and aPTT (Note: Warfarin and other coumarin derivatives are prohibited).
  8. Evidence of post-menopausal status, or negative urine or serum pregnancy test for female pre-menopausal participants. Women who have undergone surgical sterilisation (bilateral oophorectomy, bilateral salpingectomy/tubal ligation, or hysterectomy) do not require pregnancy testing. Women will be considered post-menopausal if they have been amenorrhoeic for 12 months without an alternative medical cause. The following age-specific requirements apply:

    1. Women < 50 years of age would be considered post-menopausal/non-fertile if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments or chemotherapy (whichever is most recent) and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution.
    2. b) Women ≥ 50 years of age would be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses > 1 year ago, or had chemotherapy-induced menopause with last menses > 1 year ago.

Exclusion Criteria (Pre-Registration):

Any one of the following is regarded as a criterion for exclusion from pre-registration to the study:

  1. Previously treated with:

    1. Lapatinib within 12 months of registration OR
    2. Neratinib or afatinib within 12 months of registration, unless ceased due to toxicity and not progression.
  2. Prior anti-PD-1, anti-PD-L1/L2 or anti-CTLA4 therapy, including, but not limited to: pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab, ipilimumab, tremelimumab.
  3. Previous severe hypersensitivity reaction to treatment with TKI or monoclonal antibody that is biologically similar to the study treatments.
  4. Known or suspected leptomeningeal disease as documented by the investigator.
  5. Have poorly controlled (> 1/week) generalised or complex partial seizures, or manifest neurologic progression due to brain metastases despite CNS-directed therapy.
  6. History of clinically significant or uncontrolled cardiac disease, including congestive heart failure (New York Heart Association functional classification ≥ 3), angina, myocardial infarction or ventricular arrhythmia. Have known myocardial infarction or unstable angina within 6 months before registration.
  7. Active or history of autoimmune disease or immune deficiency, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, or multiple sclerosis, with the following exceptions:

    1. History of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible
    2. Stable diabetes mellitus are eligible
    3. Eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g. patients with psoriatic arthritis are excluded) are eligible provided ALL the following conditions are met:

    i) Rash must cover < 10% of body surface area ii) Disease is well controlled at baseline and requires only low-potency topical corticosteroids iii) No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months.

  8. Known human immunodeficiency virus (HIV) (HIV1/2antibodies) or active Hepatitis B (HBsAg reactive) or Hepatitis C (HCV RNA [qualitative]).

    1. Participants with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen antibody test) are eligible
    2. Participants positive for HCV antibody are eligible only if polymerase change reaction is negative for HCV RNA.
  9. Pregnant, breastfeeding or planning a pregnancy; lactating participants must stop breast feeding before registration.
  10. Require therapy with warfarin or other coumarin derivatives (non-coumarin anticoagulants are allowed).
  11. Unable to swallow pills or has significant gastrointestinal disease which would preclude the adequate oral absorption of medications.
  12. History of or active pneumonitis/interstitial lung disease requiring treatment with steroids.
  13. History of current active tuberculosis.
  14. Has had an allogenic tissue/solid organ transplant.
  15. History of uncontrolled hypertension (≥ 180/110), dyspnoea at rest, or chronic therapy with oxygen.
  16. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.

Exclusion Criteria (Registration):

In addition to the above listed pre-registration exclusion criteria, any one of the following is regarded as a criterion for exclusion from registration to the study:

  1. Have received treatment with any systemic anti-cancer therapy (including hormonal therapy), non-CNS radiation or experimental agent within 28 days of registration, except for participants with ER-positive breast cancer.
  2. Have any toxicity related to prior cancer therapies that has not resolved to ≤ Grade 1, with the following exceptions:

    1. Alopecia
    2. Neuropathy, which must have resolved to ≤ Grade 2
    3. Menopausal symptoms.
  3. Any untreated brain lesions > 2.0 cm in size, unless discussed with BCT and Study Chair and approval for registration is given.
  4. Ongoing use of systemic corticosteroids for control of symptoms of brain metastases at a total daily dose of > 2 mg of dexamethasone (or equivalent). However, patients on a chronic stable dose of ≤ 2 mg total daily of dexamethasone (or equivalent) may be eligible with discussion and approval by BCT and the Study Chair.
  5. Any brain lesion thought to require immediate local therapy, including (but not limited to) a lesion in an anatomic site where increase in size or possible treatment-related oedema may pose risk to patient (e.g. brain stem lesions). Participants who undergo local treatment for such lesions identified by screening contrast brain MRI may still be eligible for the study based on criteria described under Registration Inclusion Criteria 4.
  6. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 450 ms from a single ECG.
  7. Use of a strong CYP2C8 inhibitor within 5 half-lives of the inhibitor, or a strong CYP3A4 or CYP2C8 inducer within 5 days before the first dose of study treatment. Use of sensitive CYP3A substrates should be avoided 2 weeks before registration and during study treatment.
  8. Treatment with botanical preparations (e.g. herbal supplements) and traditional Chinese medicines, intended for general health support or to treat the disease under study, within 7 days before registration.
  9. Active infection requiring systemic therapy.
  10. Administration of a live/live attenuated vaccine within 30 days before registration.

Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed, however intranasal influenza vaccines (e.g. FluMist®) are live attenuated vaccines and are not allowed.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04789096


Contacts
Layout table for location contacts
Contact: Heath Badger +61 2 4925 3022 heath.badger@bctrials.org.au

Locations
Layout table for location information
Australia, New South Wales
Border Medical Oncology
Albury, New South Wales, Australia, 2640
Contact: Kerrie Clarke, Dr         
Coffs Harbour Health Campus
Coffs Harbour, New South Wales, Australia, 2450
Contact: William Fox, Dr         
Gosford Hospital
Gosford, New South Wales, Australia, 2250
Contact: Susan Tiley, Dr         
Nepean Cancer Care Centre
Kingswood, New South Wales, Australia, 2747
Contact: Anuradha Vasista, Dr         
Macquarie University
Macquarie Park, New South Wales, Australia, 2109
Contact: Dhanusha Sabanathan, Dr         
Prince of Wales Hospital
Randwick, New South Wales, Australia, 2031
Contact: Kim Tam Bui, Dr         
Calvary Mater Newcastle
Waratah, New South Wales, Australia, 2310
Contact: Janine Lombard, Dr         
Westmead Hospital
Westmead, New South Wales, Australia, 2145
Contact: Rina Hui, Prof         
Australia, Queensland
Sunshine Coast University Hospital
Birtinya, Queensland, Australia, 4575
Contact: Michelle Morris, Dr         
Australia, South Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5000
Contact: Anne Taylor, Dr         
Australia, Tasmania
Icon Cancer Centre Hobart
Hobart, Tasmania, Australia, 7000
Contact: Louise Nott, A/Prof         
Australia, Victoria
Ballarat Health Services (Grampians Health)
Ballarat, Victoria, Australia, 3350
Contact: Lee na Teo, Dr         
Austin Hospital
Heidelberg, Victoria, Australia, 3084
Contact: Belinda Yeo, Dr         
Peter MacCallum Cancer Centre
Parkville, Victoria, Australia, 3002
Contact: Sherene Loi, Prof         
Epworth Richmond Hospital
Richmond, Victoria, Australia, 3121
Contact: Ross Jennens, Dr         
Sunshine Hospital
St Albans, Victoria, Australia, 3021
Contact: Catherine Oakman, Dr         
Sponsors and Collaborators
Breast Cancer Trials, Australia and New Zealand
Investigators
Layout table for investigator information
Study Director: Heath Badger Breast Cancer Trials, Australia and New Zealand
Study Chair: Sherene Loi, Prof Peter MacCallum Cancer Centre, Australia
Additional Information:
Layout table for additonal information
Responsible Party: Breast Cancer Trials, Australia and New Zealand
ClinicalTrials.gov Identifier: NCT04789096    
Other Study ID Numbers: BCT 2102
First Posted: March 9, 2021    Key Record Dates
Last Update Posted: September 6, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Data Sharing process for this study is in development and will be updated as soon as it is available.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Analytic Code
Time Frame: Data will be made available for request after publication of the main/final study results; no end date. Note that there may be additional circumstances preventing BCT from sharing requested data as outlined in the BCT Data Sharing Guidelines.
Access Criteria: Researchers need to submit a research proposal (concept@bctrials.org.au) and BCT Data Request Application, which is then assessed by BCT as having appropriate scientific value.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Pembrolizumab
Trastuzumab
Capecitabine
Tucatinib
Antineoplastic Agents, Immunological
Antineoplastic Agents
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors
Enzyme Inhibitors